<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00515879</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH078308</org_study_id>
    <secondary_id>R01MH078308</secondary_id>
    <secondary_id>R01MH075889</secondary_id>
    <nct_id>NCT00515879</nct_id>
  </id_info>
  <brief_title>Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia</brief_title>
  <official_title>D-cycloserine Enhancement of Exposure in Social Phobia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston University Charles River Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston University Charles River Campus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the effectiveness of D-cycloserine combined with cognitive-behavior
      therapy in treating people with social anxiety disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Social anxiety disorder (SAD) is among the most common psychiatric conditions and is
      associated with significant distress and dysfunction in social situations. Although treatment
      with cognitive-behavior therapy (CBT) is known to help remedy SAD, many patients do not
      respond to this treatment and most do not reach full recovery. In CBT, patients undergo
      repeated and prolonged exposure practices to feared social situations to learn better ways to
      deal with anxiety in these settings. Exposure therapy is based on animal models of extinction
      of conditioned fears, and recent animal research has identified some of the core pathways and
      neurotransmitters involved in fear extinction. D-cycloserine (DCS) is a drug that appears to
      facilitate learning and the process of extinction of conditioned fear in both animals and
      humans. This study will assess the effectiveness of DCS combined with CBT in treating people
      with SAD.

      Participants in this double-blind study will be randomly assigned to an active or control
      group. All participants will attend 18 study visits at the Center for Anxiety and Related
      Disorders over a 9-month period. There will be 12 CBT sessions of 90 minutes each and 6
      assessment visits. The CBT sessions will help participants to become more comfortable with
      social situations. During 5 of the CBT sessions, participants will receive a pill containing
      either DCS or sugar (placebo). Assessment visits will include interviews, self-report
      questionnaires, and laboratory tests. These visits will occur at Weeks 1, 7, and 12 during
      treatment and at Months 3, 6, and 9 post-treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Social Phobic Disorders Severity and Change Form</measure>
    <time_frame>Measured at Months 3 (immediately after treatment)</time_frame>
    <description>Social Phobic Disorders Severity and Change Form (SPD-SC Form; Liebowitz et al., 1992) is an expansion and adaptation of the Clinical Global Impression Scale (CGI) by Guy (1976) to SAD. Similar to the original CGI scale, the SPD-SC Form is rated by an independent evaluator on a 7-point scale to indicate severity (1=normal/not ill; 2 = minimally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most severely ill) and improvement (1=very much improved; 2=much improved; . 3=minimally improved' 4 = no change; 5=nimimal deterioration; 6=severe deterioration; 7=very severe deterioration). The primary outcome measure is units of a scale ranging from 1 (very much improved) to 7 (very severe deterioration).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liebowitz Social Anxiety Scale (LSAS)</measure>
    <time_frame>Measured at Months 3</time_frame>
    <description>The Liebowitz Social Anxiety Scale (LSAS; Liebowitz, 1987) is a 24-item scale that provides separate scores for fear and avoidance in social and performance situations; it is widely used in treatment studies of SAD. Total scores range from 0 (no anxiety) to 144 (maximum).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Social Phobia and Anxiety Inventory</measure>
    <time_frame>Measured at Months 3, 6, and 9 post-treatment</time_frame>
    <description>The Social Phobia and Anxiety Inventory (SPAI; Turner, Beidel, Dancu, and Stanley, 1989) is a 45-item self-report measure on the frequency (0 = Never, 1 = Very Infrequent, 2 = Infrequent, 3 = Sometimes, 4 = Frequent, 5 = Very Frequent, 6 = Always) of one's experiences. The inventory includes 32 items assessing somatic, cognitive, and behavioral symptoms of social anxiety and 13 items assessing agoraphobia. The final score is calculated by subtracting the agoraphobia subscale total (max = 78; min = 0) from the social phobia subscale total (max = 192; min = 0). Thus, the final total scores range from 0-114, where higher final scores indicate higher social anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Enjoyment and Satisfaction Questionnaire</measure>
    <time_frame>Measured at Months 3, 6, and 9 post-treatment</time_frame>
    <description>The Quality of Life Enjoyment and Satisfaction Questionnaire (Endicott et al., 1993) is a 16-item self-report measure that rates aspects of quality of life, including physical health, mood, activities of daily living, and overall life satisfaction. Responses are scored on a 5 point scale. The maximum score is 70 (high satisfaction) and the minimum is 14 (low satisfaction); scores are generally expressed as a percentage of maximum total score (0-100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liebowitz Self-Rated Disability Scale</measure>
    <time_frame>Measured at Months 3, 6, and 9 post-treatment</time_frame>
    <description>Liebowitz Self-Rated Disability Scale (Schneier et al., 1994) is an 11-item scale assessing impairment specific to social anxiety. Current (past 2 weeks) and most severe lifetime impairment due to social anxiety disorder are rated on a 0-3 scale of degree of limitation (0=problem does not limit me at all; 3=problem limits me severely). The maximum score is 44 (severe impairment) and the minimum is 0 (no impairment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Range of Impaired Functioning Tool</measure>
    <time_frame>Measured at Months 3, 6, and 9 post-treatment</time_frame>
    <description>The Range of Impaired Functioning Tool (LIFE-RIFT, Leon et al., 2000) is a clinician rated scale assessing functioning in four domains: work, interpersonal relationships, recreation, and global satisfaction. Each domain is scored 0-5 (0=not applicable, 1=no impairment, 2=slight impairment, 3=mild impairment, 4=moderate impairment, 5=severe impairment). The total score is the sum of each domain's score, with a maximum score of 20 (severe impairment) and a minimum score of 4 (no impairment).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">169</enrollment>
  <condition>Social Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>CBT plus d-cycloserine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive cognitive behavioral therapy plus D-cycloserine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBT plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive cognitive behavioral therapy plus pill placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-cycloserine</intervention_name>
    <description>50 mg</description>
    <arm_group_label>CBT plus d-cycloserine</arm_group_label>
    <other_name>Seromycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive behavioral therapy (CBT)</intervention_name>
    <description>CBT sessions aim to help participants become more comfortable with social situations.</description>
    <arm_group_label>CBT plus d-cycloserine</arm_group_label>
    <arm_group_label>CBT plus placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Same dosage as active pill</description>
    <arm_group_label>CBT plus placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets DSM-IV criteria for generalized social anxiety disorder (GSAD)

          -  Total score of greater than or equal to 60 on the LSAS

          -  Physical examination, electrocardiogram, and laboratory findings without clinically
             significant abnormalities

        Exclusion Criteria:

          -  Lifetime history of bipolar disorder, schizophrenia, psychosis, delusional disorders,
             or obsessive-compulsive disorder

          -  Eating disorder within the 6 months prior to study entry

          -  History of organic brain syndrome, mental retardation, or other cognitive dysfunction

          -  Substance or alcohol abuse or dependence (other than nicotine) within the 6 months
             prior to study entry or inability to refrain from alcohol use during the acute period
             of study participation

          -  Post-traumatic stress disorder within 6 months prior to study entry; entry of patients
             with other mood or anxiety disorders will be permitted if the social anxiety disorder
             is judged to be the predominant disorder

          -  Suicidal thoughts

          -  Taking concurrent psychotropic medication (e.g., antidepressants, anxiolytics, beta
             blockers) within 2 weeks of study entry

          -  Significant personality dysfunction

          -  Serious medical illness or instability for which hospitalization may be likely within
             the next year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan G. Hofmann, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark H. Pollack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jasper A. Smits, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Southern Methodist University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.socialanxietyboston.com/</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Hofmann SG, Pollack MH, Otto MW. Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine. CNS Drug Rev. 2006 Fall-Winter;12(3-4):208-17. Review.</citation>
    <PMID>17227287</PMID>
  </reference>
  <reference>
    <citation>Otto MW, Basden SL, Leyro TM, McHugh RK, Hofmann SG. Clinical perspectives on the combination of D-cycloserine and cognitive-behavioral therapy for the treatment of anxiety disorders. CNS Spectr. 2007 Jan;12(1):51-6, 59-61. Review.</citation>
    <PMID>17192764</PMID>
  </reference>
  <reference>
    <citation>Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, Shiekh M, Otto MW. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006 Mar;63(3):298-304.</citation>
    <PMID>16520435</PMID>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>August 10, 2007</study_first_submitted>
  <study_first_submitted_qc>August 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2007</study_first_posted>
  <results_first_submitted>August 2, 2013</results_first_submitted>
  <results_first_submitted_qc>July 20, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 23, 2015</results_first_posted>
  <last_update_submitted>February 5, 2019</last_update_submitted>
  <last_update_submitted_qc>February 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston University Charles River Campus</investigator_affiliation>
    <investigator_full_name>Stefan G. Hofmann</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Generalized subtype</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Phobia, Social</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cycloserine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Prospective participants were recruited between September 2007 and June 2011 through referrals to the three study sites (Boston University [BU], Massachusetts General Hospital [MGH], and Southern Methodist University [SMU]), from other area clinical facilities and programs, and from advertisements.</recruitment_details>
      <pre_assignment_details>Study participants underwent a two-step screening evaluation, consisting of 1) telephone screening, and 2) psychiatric assessment and medical history taking with physical examination.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>D-cycloserine-augmented CBT</title>
          <description>Participants will receive D-cycloserine augmented cognitive behavioral therapy</description>
        </group>
        <group group_id="P2">
          <title>Placebo-augmented CBT</title>
          <description>Participants will receive placebo augmented cognitive behavioral therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>D-cycloserine-augmented CBT</title>
          <description>Participants will receive D-cycloserine augmented cognitive behavioral therapy</description>
        </group>
        <group group_id="B2">
          <title>Placebo-augmented CBT</title>
          <description>Participants will receive placebo augmented cognitive behavioral therapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="87"/>
            <count group_id="B2" value="82"/>
            <count group_id="B3" value="169"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="169"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.6" spread="7.89"/>
                    <measurement group_id="B2" value="30.5" spread="8.9"/>
                    <measurement group_id="B3" value="32.55" spread="8.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Social Phobic Disorders Severity and Change Form</title>
        <description>Social Phobic Disorders Severity and Change Form (SPD-SC Form; Liebowitz et al., 1992) is an expansion and adaptation of the Clinical Global Impression Scale (CGI) by Guy (1976) to SAD. Similar to the original CGI scale, the SPD-SC Form is rated by an independent evaluator on a 7-point scale to indicate severity (1=normal/not ill; 2 = minimally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most severely ill) and improvement (1=very much improved; 2=much improved; . 3=minimally improved' 4 = no change; 5=nimimal deterioration; 6=severe deterioration; 7=very severe deterioration). The primary outcome measure is units of a scale ranging from 1 (very much improved) to 7 (very severe deterioration).</description>
        <time_frame>Measured at Months 3 (immediately after treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D-cycloserine-augmented CBT</title>
            <description>Participants will receive D-cycloserine augmented cognitive behavioral therapy</description>
          </group>
          <group group_id="O2">
            <title>Placebo-augmented CBT</title>
            <description>Participants will receive placebo augmented cognitive behavioral therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Social Phobic Disorders Severity and Change Form</title>
          <description>Social Phobic Disorders Severity and Change Form (SPD-SC Form; Liebowitz et al., 1992) is an expansion and adaptation of the Clinical Global Impression Scale (CGI) by Guy (1976) to SAD. Similar to the original CGI scale, the SPD-SC Form is rated by an independent evaluator on a 7-point scale to indicate severity (1=normal/not ill; 2 = minimally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most severely ill) and improvement (1=very much improved; 2=much improved; . 3=minimally improved' 4 = no change; 5=nimimal deterioration; 6=severe deterioration; 7=very severe deterioration). The primary outcome measure is units of a scale ranging from 1 (very much improved) to 7 (very severe deterioration).</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68" lower_limit="2.38" upper_limit="2.98"/>
                    <measurement group_id="O2" value="2.95" lower_limit="2.64" upper_limit="3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Liebowitz Social Anxiety Scale (LSAS)</title>
        <description>The Liebowitz Social Anxiety Scale (LSAS; Liebowitz, 1987) is a 24-item scale that provides separate scores for fear and avoidance in social and performance situations; it is widely used in treatment studies of SAD. Total scores range from 0 (no anxiety) to 144 (maximum).</description>
        <time_frame>Measured at Months 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D-cycloserine-augmented CBT</title>
            <description>Participants will receive D-cycloserine augmented cognitive behavioral therapy</description>
          </group>
          <group group_id="O2">
            <title>Placebo-augmented CBT</title>
            <description>Participants will receive placebo augmented cognitive behavioral therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Liebowitz Social Anxiety Scale (LSAS)</title>
          <description>The Liebowitz Social Anxiety Scale (LSAS; Liebowitz, 1987) is a 24-item scale that provides separate scores for fear and avoidance in social and performance situations; it is widely used in treatment studies of SAD. Total scores range from 0 (no anxiety) to 144 (maximum).</description>
          <units>LSAS scores</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.19" lower_limit="34.79" upper_limit="43.59"/>
                    <measurement group_id="O2" value="42.44" lower_limit="37.94" upper_limit="47.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Social Phobia and Anxiety Inventory</title>
        <description>The Social Phobia and Anxiety Inventory (SPAI; Turner, Beidel, Dancu, and Stanley, 1989) is a 45-item self-report measure on the frequency (0 = Never, 1 = Very Infrequent, 2 = Infrequent, 3 = Sometimes, 4 = Frequent, 5 = Very Frequent, 6 = Always) of one's experiences. The inventory includes 32 items assessing somatic, cognitive, and behavioral symptoms of social anxiety and 13 items assessing agoraphobia. The final score is calculated by subtracting the agoraphobia subscale total (max = 78; min = 0) from the social phobia subscale total (max = 192; min = 0). Thus, the final total scores range from 0-114, where higher final scores indicate higher social anxiety.</description>
        <time_frame>Measured at Months 3, 6, and 9 post-treatment</time_frame>
        <population>The number of analyzed participants differs from the overall number analyzed due to participant dropout between treatment and subsequent follow up time points.</population>
        <group_list>
          <group group_id="O1">
            <title>D-cycloserine-augmented CBT</title>
            <description>Participants will receive D-cycloserine augmented cognitive behavioral therapy</description>
          </group>
          <group group_id="O2">
            <title>Placebo-augmented CBT</title>
            <description>Participants will receive placebo augmented cognitive behavioral therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Social Phobia and Anxiety Inventory</title>
          <description>The Social Phobia and Anxiety Inventory (SPAI; Turner, Beidel, Dancu, and Stanley, 1989) is a 45-item self-report measure on the frequency (0 = Never, 1 = Very Infrequent, 2 = Infrequent, 3 = Sometimes, 4 = Frequent, 5 = Very Frequent, 6 = Always) of one's experiences. The inventory includes 32 items assessing somatic, cognitive, and behavioral symptoms of social anxiety and 13 items assessing agoraphobia. The final score is calculated by subtracting the agoraphobia subscale total (max = 78; min = 0) from the social phobia subscale total (max = 192; min = 0). Thus, the final total scores range from 0-114, where higher final scores indicate higher social anxiety.</description>
          <population>The number of analyzed participants differs from the overall number analyzed due to participant dropout between treatment and subsequent follow up time points.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.08" spread="28.585"/>
                    <measurement group_id="O2" value="73.74" spread="30.311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.64" spread="32.188"/>
                    <measurement group_id="O2" value="71.97" spread="30.566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.67" spread="31.847"/>
                    <measurement group_id="O2" value="67.74" spread="33.289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Enjoyment and Satisfaction Questionnaire</title>
        <description>The Quality of Life Enjoyment and Satisfaction Questionnaire (Endicott et al., 1993) is a 16-item self-report measure that rates aspects of quality of life, including physical health, mood, activities of daily living, and overall life satisfaction. Responses are scored on a 5 point scale. The maximum score is 70 (high satisfaction) and the minimum is 14 (low satisfaction); scores are generally expressed as a percentage of maximum total score (0-100).</description>
        <time_frame>Measured at Months 3, 6, and 9 post-treatment</time_frame>
        <population>The number of analyzed participants differs from the overall number analyzed due to participant dropout between treatment and subsequent follow up time points.</population>
        <group_list>
          <group group_id="O1">
            <title>D-cycloserine-augmented CBT</title>
            <description>Participants will receive D-cycloserine augmented cognitive behavioral therapy</description>
          </group>
          <group group_id="O2">
            <title>Placebo-augmented CBT</title>
            <description>Participants will receive placebo augmented cognitive behavioral therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Enjoyment and Satisfaction Questionnaire</title>
          <description>The Quality of Life Enjoyment and Satisfaction Questionnaire (Endicott et al., 1993) is a 16-item self-report measure that rates aspects of quality of life, including physical health, mood, activities of daily living, and overall life satisfaction. Responses are scored on a 5 point scale. The maximum score is 70 (high satisfaction) and the minimum is 14 (low satisfaction); scores are generally expressed as a percentage of maximum total score (0-100).</description>
          <population>The number of analyzed participants differs from the overall number analyzed due to participant dropout between treatment and subsequent follow up time points.</population>
          <units>percentage of maximum</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.77" spread="14.075"/>
                    <measurement group_id="O2" value="67.44" spread="14.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.32" spread="16.066"/>
                    <measurement group_id="O2" value="67.44" spread="14.872"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.08" spread="16.063"/>
                    <measurement group_id="O2" value="69.58" spread="11.761"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liebowitz Self-Rated Disability Scale</title>
        <description>Liebowitz Self-Rated Disability Scale (Schneier et al., 1994) is an 11-item scale assessing impairment specific to social anxiety. Current (past 2 weeks) and most severe lifetime impairment due to social anxiety disorder are rated on a 0-3 scale of degree of limitation (0=problem does not limit me at all; 3=problem limits me severely). The maximum score is 44 (severe impairment) and the minimum is 0 (no impairment).</description>
        <time_frame>Measured at Months 3, 6, and 9 post-treatment</time_frame>
        <population>The number of analyzed participants differs from the overall number analyzed due to participant dropout between treatment and subsequent follow up time points.</population>
        <group_list>
          <group group_id="O1">
            <title>CBT Plus D-cycloserine</title>
            <description>Participants will receive cognitive behavioral therapy plus D-cycloserine
D-cycloserine: 50 mg
Cognitive behavioral therapy (CBT): CBT sessions aim to help participants become more comfortable with social situations.</description>
          </group>
          <group group_id="O2">
            <title>CBT Plus Placebo</title>
            <description>Participants will receive cognitive behavioral therapy plus pill placebo
Cognitive behavioral therapy (CBT): CBT sessions aim to help participants become more comfortable with social situations.
Placebo: Same dosage as active pill</description>
          </group>
        </group_list>
        <measure>
          <title>Liebowitz Self-Rated Disability Scale</title>
          <description>Liebowitz Self-Rated Disability Scale (Schneier et al., 1994) is an 11-item scale assessing impairment specific to social anxiety. Current (past 2 weeks) and most severe lifetime impairment due to social anxiety disorder are rated on a 0-3 scale of degree of limitation (0=problem does not limit me at all; 3=problem limits me severely). The maximum score is 44 (severe impairment) and the minimum is 0 (no impairment).</description>
          <population>The number of analyzed participants differs from the overall number analyzed due to participant dropout between treatment and subsequent follow up time points.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6117" spread="7.25681"/>
                    <measurement group_id="O2" value="14.0303" spread="7.79688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5283" spread="7.03686"/>
                    <measurement group_id="O2" value="14.4977" spread="7.98470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3269" spread="7.72461"/>
                    <measurement group_id="O2" value="14.3130" spread="7.62630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Range of Impaired Functioning Tool</title>
        <description>The Range of Impaired Functioning Tool (LIFE-RIFT, Leon et al., 2000) is a clinician rated scale assessing functioning in four domains: work, interpersonal relationships, recreation, and global satisfaction. Each domain is scored 0-5 (0=not applicable, 1=no impairment, 2=slight impairment, 3=mild impairment, 4=moderate impairment, 5=severe impairment). The total score is the sum of each domain's score, with a maximum score of 20 (severe impairment) and a minimum score of 4 (no impairment).</description>
        <time_frame>Measured at Months 3, 6, and 9 post-treatment</time_frame>
        <population>The number of analyzed participants differs from the overall number analyzed due to participant dropout between treatment and subsequent follow up time points.</population>
        <group_list>
          <group group_id="O1">
            <title>D-cycloserine-augmented CBT</title>
            <description>Participants will receive D-cycloserine augmented cognitive behavioral therapy</description>
          </group>
          <group group_id="O2">
            <title>Placebo-augmented CBT</title>
            <description>Participants will receive placebo augmented cognitive behavioral therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Range of Impaired Functioning Tool</title>
          <description>The Range of Impaired Functioning Tool (LIFE-RIFT, Leon et al., 2000) is a clinician rated scale assessing functioning in four domains: work, interpersonal relationships, recreation, and global satisfaction. Each domain is scored 0-5 (0=not applicable, 1=no impairment, 2=slight impairment, 3=mild impairment, 4=moderate impairment, 5=severe impairment). The total score is the sum of each domain's score, with a maximum score of 20 (severe impairment) and a minimum score of 4 (no impairment).</description>
          <population>The number of analyzed participants differs from the overall number analyzed due to participant dropout between treatment and subsequent follow up time points.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5256" spread="2.780"/>
                    <measurement group_id="O2" value="8.6667" spread="2.80841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6143" spread="2.67730"/>
                    <measurement group_id="O2" value="8.5430" spread="2.82987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6232" spread="2.80284"/>
                    <measurement group_id="O2" value="7.7458" spread="2.43957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>D-cycloserine-augmented CBT</title>
          <description>Participants will receive D-cycloserine augmented cognitive behavioral therapy</description>
        </group>
        <group group_id="E2">
          <title>Placebo-augmented CBT</title>
          <description>Participants will receive placebo augmented cognitive behavioral therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Stefan G. Hofmann, Ph.D., Professor of Psychology</name_or_title>
      <organization>Boston University</organization>
      <phone>617 353 9233</phone>
      <email>shofmann@bu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

